Welcome to our dedicated page for Trulieve Cannabis SEC filings (Ticker: TCNNF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trulieve Cannabis Corp. filings document the regulatory record of a British Columbia cannabis issuer operating as a vertically integrated multi-state operator in the U.S. Recent Form 8-K reports cover operating results, Regulation FD presentations, material definitive agreements, executive compensation matters, and board or officer transitions.
Proxy filings describe annual meeting matters, director elections, executive compensation, equity awards, and shareholder governance. Debt-related filings disclose senior secured notes due 2030, indenture terms, subsidiary guarantees, and related capital-structure obligations tied to Trulieve and its restricted subsidiaries.
Trulieve Cannabis Corp. Chairman and CEO Kim A. Rivers reported open-market sales of 482,196 Subordinate Voting Shares. These sales occurred on June 17, 18 and 22, 2026 at weighted average prices around $9.35–$9.46 per share under transaction code S.
The filing notes these transactions were effected pursuant to a Rule 10b5-1 plan to sell 2.5 million shares adopted on March 16, 2026, with a Form 144 covering a first tranche of 1,699,007 Subordinate Voting Shares filed on June 17, 2026. Following the reported sales, Rivers directly holds 2,693,724 Subordinate Voting Shares.
She also has Multiple Voting Shares convertible into 15,166,700 Subordinate Voting Shares directly and 986,700 Subordinate Voting Shares indirectly through Traunch IV LLC, as disclosed in the derivative holdings and related footnotes.
Trulieve Cannabis Corp. Chairman and CEO Kim A. Rivers reported open-market sales of 482,196 Subordinate Voting Shares. These sales occurred on June 17, 18 and 22, 2026 at weighted average prices around $9.35–$9.46 per share under transaction code S.
The filing notes these transactions were effected pursuant to a Rule 10b5-1 plan to sell 2.5 million shares adopted on March 16, 2026, with a Form 144 covering a first tranche of 1,699,007 Subordinate Voting Shares filed on June 17, 2026. Following the reported sales, Rivers directly holds 2,693,724 Subordinate Voting Shares.
She also has Multiple Voting Shares convertible into 15,166,700 Subordinate Voting Shares directly and 986,700 Subordinate Voting Shares indirectly through Traunch IV LLC, as disclosed in the derivative holdings and related footnotes.
Wilson Davis submitted a Form 144 notice relating to proposed sales of Subordinate Voting Shares of Trulieve Cannabis Corp. The filing lists multiple grant dates and share lots tied to RSU award agreements and a merger agreement, including several specific share amounts and dates.
The excerpt shows RSU-related lots such as 19,700 shares (12/29/2022), 44,354 shares (12/29/2023), 1,439,662 shares (09/17/2024), and others; additional lots include 59,301, 19,765, 98,289, and 17,936 with their respective award dates. The filer is identified at an address in Salt Lake City and the exchange listed is NYSE.
Wilson Davis submitted a Form 144 notice relating to proposed sales of Subordinate Voting Shares of Trulieve Cannabis Corp. The filing lists multiple grant dates and share lots tied to RSU award agreements and a merger agreement, including several specific share amounts and dates.
The excerpt shows RSU-related lots such as 19,700 shares (12/29/2022), 44,354 shares (12/29/2023), 1,439,662 shares (09/17/2024), and others; additional lots include 59,301, 19,765, 98,289, and 17,936 with their respective award dates. The filer is identified at an address in Salt Lake City and the exchange listed is NYSE.
Trulieve Cannabis Corp. is asking shareholders to approve a Plan of Arrangement to continue the company from British Columbia to Delaware (the “Delaware Domestication”) at a virtual special meeting on August 5, 2026. The Board recommends voting FOR the Arrangement Resolution and for an adjournment proposal to solicit additional proxies if needed.
The domestication would convert each Subordinate Voting Share and Multiple Voting Share into identical Delaware-class shares, preserve existing options, RSUs and PSUs on equivalent terms, keep outstanding debt (including the 10.5% senior secured notes due December 17, 2030), and set an initial board size of seven with amended authorized share capital. The Plan is subject to shareholder approval, a final court order in British Columbia and other customary conditions.
Trulieve Cannabis Corp. announced that President Jason Pernell has terminated his employment and his role as President effective June 11, 2026. The parties entered into a Separation Agreement and General Release that includes mutual releases of certain claims.
Mr. Pernell agreed not to sell, transfer, or otherwise monetize his Trulieve subordinate voting shares or other equity securities held in his name for one year from the Separation Agreement date. In return, and contingent on his compliance with the agreement, he remains eligible for his second quarter 2026 performance bonus and a prorated portion of his 2026 target performance bonus after 2026 earnings, receives a $15,000 severance payment, continued COBRA medical, dental, and vision premiums for up to 18 months or until he obtains similar coverage, and vesting of any issued and unvested annual equity awards as of the termination date.
Trulieve Cannabis Corp. reported results from its annual shareholder meeting, where investors approved all proposals on the agenda. Shareholders set the board size at seven directors, with 107,646,420 votes for and 1,235,766 against.
All seven director nominees were elected, each receiving over 48.9 million votes for, with substantial broker non-votes reflecting shares not voted on these items. Investors also backed, on a non-binding basis, the 2025 compensation of named executive officers, with 49,752,239 votes for and 1,997,073 against.
Shareholders ratified the appointment of WithumSmith+Brown, PC as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 107,441,983 votes for and 1,169,382 against. The filing also includes an Inline XBRL cover page data exhibit.
Trulieve Cannabis Corp. announced that its board authorized a share repurchase program allowing the company to buy back up to the lesser of $50 million in aggregate value or 8,495,038 subordinate voting shares, representing 5% of issued and outstanding subordinate voting shares as of June 8, 2026.
The program runs over a 12-month period and will expire on June 16, 2027. Trulieve is not obligated to repurchase any specific number of shares and may suspend, modify, or discontinue the program at its discretion, and any repurchased shares will be cancelled.
Trulieve Cannabis Corp. has completed a major restructuring of its U.S. operations by deconsolidating its former indirectly wholly owned subsidiary, Harvest Enterprises, LLC, into a separately controlled entity focused on mixed-use cannabis. Trulieve now holds only non-voting, non-participating units in Harvest, which are convertible into voting units only after a future “Stock Exchange Permissibility Date” when the NYSE permits consolidation of U.S. non-medical cannabis businesses. A new investor, Whitley Holding 05192026, LLC, acquired Class A voting units representing a 10% economic interest in Harvest for approximately $14.8 million and controls two of three board seats.
The transaction is designed to segregate Trulieve’s mixed-use cannabis business from its medical cannabis business so it can apply to list its subordinate voting shares on the New York Stock Exchange. Pro forma financials show Harvest removed from Trulieve’s historical results and the retained interest now accounted for under the equity method, with an estimated pre-tax loss on deconsolidation of about $688.7 million.
Trulieve Cannabis Corp. reported mixed Q1 2026 results. Revenue was $286.8 million, down about 4% year over year as retail sales declined on price compression, partly offset by stronger wholesale revenue. Gross margin slipped to 59.3% from 61.5%.
The company generated net income of $2.3 million versus a $33.8 million loss a year earlier, helped by sharply lower campaign and political spending and a smaller tax provision. Adjusted EBITDA was $100.4 million, or 35.0% of revenue. Cash and cash equivalents rose to $352.9 million, supported by $55.7 million of operating cash flow and new private placement debt. Management highlighted the U.S. decision to reschedule medical cannabis to Schedule III and its applications for DEA licenses in key medical markets as a structural shift in its tax and regulatory profile.
Trulieve Cannabis Corp. reported a profitable first quarter of 2026, generating revenue of $286.8 million and net income attributable to common shareholders of $2.4 million, after a loss a year earlier. Gross profit was $170.1 million, for a gross margin of about 59%.
The company produced adjusted EBITDA of $100.4 million, equal to a 35% margin, and free cash flow of $42.2 million from operating cash flow of $55.7 million and capital expenditures of $13.5 million. Cash rose to $352.9 million at March 31, 2026, while debt, including private placement notes, totaled $290 million at a 9.6% interest rate.
Management expects 2026 cash flow from operations of at least $250 million and capital expenditures of up to $85 million, and anticipates second-quarter 2026 revenue will increase by a low single-digit percentage versus the first quarter. The company highlighted U.S. federal rescheduling of medical marijuana to Schedule III, has applied for Drug Enforcement Agency registration for 206 state-licensed medical locations, and now operates 240 retail dispensaries and over four million square feet of cultivation and processing capacity.